Denver Nuggets guard Gary Harris wearing a Masimo MightySat pulse oximeter. (Image from Masimo/NBA)
Masimo
Share price on Dec. 31, 2019: $158.06
Share price on Dec. 31, 2020: $268.38
Change: +70%
As the public began to understand more and more about COVID-19, Masimo (NSDQ:MASI) and its pulse oximeter technology began to come to the fore.
Stores were selling out of pulse oximeters back in the spring of 2020 as it was suggested that they could help identify COVID-19 infection at home, and Masimo suddenly took a central role in the fight against the virus.
Irvine, Calif.-based Masimo even entered into a partnership with the National Basketball Association to become its official supplier of pulse oximetry when the NBA returned to action after a long layoff in a “bubble” format. The company continued to produce pulse oximetry and patient monitoring on a number of levels in 2020, including:
- Receiving FDA 510(k) clearance for its handheld Rad-G pulse oximeter.
- Expanded FDA clearance for its O3 Regional Oximetry device.
- FDA clearance for its PVi (pleth variability index) for fluid responsiveness indication in ventilated adult patients.
- FDA clearance for its Centroid wireless orientation, activity and respiration rate sensor.
- FDA de novo classification for its Bridge neuromodulation-based opioid withdrawal device.
- Launching its UniView: 60 hospital automation platform.
- Launching its SafetyNet-Open monitor designed to help businesses, governments and schools manage employee and student health and safety during the pandemic.
All those advances for Masimo helped with the company on the financial and M&A front, as it also acquired advanced hemodynamic monitoring device maker Lidco for approximately $40.1 million near the end of the year, having already bought German ventilation company TNI Medical for an undisclosed amount back in March 2020.
Masimo’s efforts across the board in 2020 contributed to its massive market growth and may continue to do so in 2021.
